Table 3.
Risk of developing a renal relapse during the follow-up according to the positivity of anti-nucleosome antibodies at baseline. Univariate analysis.
| Time of follow-up | Rates of relapse n, (%) |
No relapse n (%) |
RR | 95% CI | p |
|---|---|---|---|---|---|
| (a) Renal relapse | |||||
| Follow-up: 6 months | |||||
| Anti-NCS (+) n = 18 | 5 (27.8) | 13 (72.2) | 3.85 | 1.37–10.79 | 0.02 |
| Anti-NCS (−) n = 97 | 7 (7.2) | 90 (92.8) | |||
| Follow-up: 12 months | |||||
| Anti-NCS (+) n = 18 | 7 (38.9) | 11 (61.1) | 2.90 | 1.35–6.26 | 0.016 |
| Anti-NCS (−) n = 97 | 13 (13.4) | 84 (86.6) | |||
| (b) Any type of relapse | |||||
| Follow-up: 6 months | |||||
| Anti-NCS (+) n = 18 | 4 (22.2) | 14 (77.8) | 1.08 | 0.42–2.78 | 1.00 |
| Anti-NCS (−) n = 97 | 20 (20.6) | 77 (79.4) | |||
| Follow-up: 12 months | |||||
| Anti-NCS (+) n = 18 | 9 (50.0) | 9 (50.0) | 1.31 | 0.77–2.22 | 0.43 |
| Anti-NCS (−) n = 97 | 37 (38.1) | 60 (61.9) | |||
The incidence was computed according to the accumulative incidence. Anti-NCS (−): Negative anti-nucleosome antibody titres. Anti-NCS (+): Positive anti-nucleosome antibody titres. Anti-NCS (+) was considered when ≥ 14 RU/mL.